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Abstract: The development of effective treatments for psychiatric disease has been disappointing in recent decades given
the advancements in neuroscience. Moreover, rising rates of mental illness such as addiction and depression compel
scientists and physicians to discover novel and creative solutions. One such approach that has proven effective is
systems neuroscience: A focus on networks as opposed to mechanism. Further, investigation at the single-cell and
circuit level is likely to be fruitful in such endeavors as this resolution describes the functional psychopathology that
allows for intervention.

Introduction
Rates and severity of mental illness in the United States have
risen over the past decade (“Key Substance Use and Mental
Health Indicators in the United States: Results from the 2019
National Survey on Drug Use and Health” 2020; Merikangas
et al., 2010; NIMH, 2020). Infection by the novel coronavirus
and indirect effects of the pandemic on mental health suggest
this increase is likely to continue and possibly accelerate
(Vindegaard and Benros, 2020; Taquet et al., 2020). In
addition to individual suffering, the socioeconomic and
politico-cultural consequences of this rise in mental illness
compels investigators and clinicians alike towards realizing
novel understandings and treatments as canonical psychiatric
therapies are often burdened by low efﬁcacy, high side-effect
proﬁles, and ballooning costs (Holmes et al., 2014; Holmes et
al., 2018; Ford and Young, 2021).
Neuropsychopathology studies, like virtually all
biological investigation, are performed under the guise that
the data from the experiments will eventually contribute to
clinical treatment. Though neuroscientiﬁc understanding
has developed rapidly in recent decades, novel psychiatric
therapies remain elusive (Holmes et al., 2014; Holmes et al.,
2018; Ford and Young, 2021). Even the recent psychedelic
revolution is a rediscovery of medications from half a
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century prior (Johnson et al., 2019). The demand for
efﬁcacious clinical treatments with minimal side effects,
however, remains high which galvanizes investigator
creativity raising the attractiveness of newer approaches to
neuropsychopathology such as systems biology.
Systems biology distinguishes itself from hypothesisdriven research in that understanding networks is the
primary objective as opposed to elucidating mechanisms
(Ideker et al., 2001; Geschwind and Konopka, 2009). This
difference shifts experimentation towards highthroughput
measures at multiple levels of biological systems with an
emphasis on physiological context and mathematical
modeling. Experimental designs with such broad parameters
that do not isolate individual variables had been previously
untenable because of cost and reliability; However, advances
in biotechnologies and computer science have diminished
such barriers (Geschwind and Konopka, 2009). Moreover,
this approach emphasizes network states and thus avoids
the challenges of determining causality that are inherent in
psychiatry (Stojanov et al., 2011).
Indeed, the dam of systems neuroscience has burst, and
datasets ﬁlled with pearls are ﬂooding the ﬁeld. At the level
of organ systems, visceral feedback to central centers has
been shown to have profound effects on mental health
(Critchley and Harrison, 2013). The gut-brain connection
has proven particularly powerful as intestinal microﬂora
composition consistently demonstrate behavioral inﬂuence
(Sylvia and Demas, 2018). Moreover, developments in
imaging have allowed investigators to map neural modules
www.techscience.com/journal/biocell
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and their relationships to psychopathology. This has led to the
development of neuromodulatory interventions such as
transcranial magnetic stimulation that is now Food and Drug
Administration (FDA) approved for treatment-resistant
depression and obsessive-compulsive disorder (Horvath et al.,
2010; Voelker, 2018). At the molecular level, genetic
sequencing and transcriptome measures are yielding datadriven models of cellular signaling networks that challenge
prior notions of neuronal phenotypes (Park et al., 2014).
The emergence of single cell studies is particularly
fruitful in this new frontier (Callaway, 2005). Nervous
tissue contains many kinds of cells ranging from various
types of neurons to astrocytes, oligodendrocytes, microglia,
endothelial cells, and so on. The ﬁring of any individual
neuron—which, en masse, is still believed to be the modus
for perception, thought, and behavior—is known to be
inﬂuenced by the context in which that neuron ﬁnds itself
(Pereira and Furlan, 2010; Callaway, 2005). Anatomic
localization within a network, the neighboring neurons,
synaptic and non-synaptic inputs, local paracrine signaling
and glial inﬂuences in combination determine the role of
that neuron within the network and its output. The
complexity of this dance may never be fully understood
even with quantum computers (Schiffer, 2019), but singlecell systems neuroscience is beginning to point us towards
the prominent concepts at this level that elude mechanistic
molecular studies and tissue-level or higher approaches.
That is, single-cell studies are in a Goldilocks zone of
biological levels for neuropsychopathology investigation—as
signaling networks and circuits are deciphered at this level,
knowledge of normal physiology and pathophysiology in
mental illness is likely to translate to clinical treatments
(Ford and Young, 2021).
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An example of this approach is our recent work measuring
the effects of opioid withdrawal on gene expression in single
brain cells in the central nucleus of the amygdala (CeA) of
rats (O’Sullivan et al., 2019). We combined single-cell laser
capture microdissection with microﬂuidic RT-qPCR to
measure a selected transcriptome of neurons, microglia, and
astrocytes with anatomic speciﬁcity (O’Sullivan et al., 2020).
The pre-experimental hypothesis, based on our prior
hypothesis-generating work (Freeman et al., 2012a; Freeman et
al., 2013; Freeman et al., 2012b), was that neuroinﬂammation,
likely originating from microglia, would be present 24 hours
following acute naltrexone-precipitated opioid withdrawal.
Rather, we found a striking transcriptional response in
astrocytes. A review of the literature contextualized this ﬁnding
and led us to a profound conjecture—that neuroinﬂammation
mediated by astrocytes in the CeA contributes to the negative
emotion characteristic of opioid withdrawal and that this
neuroinﬂammation increases the negative reinforcement of
withdrawal (O’Sullivan and Schwaber, 2021). Moreover, this
work translates to other levels of biological systems including
molecular signaling, organ systems, and behavior, and has
implications for the mechanisms of action of new therapies.
Astrocytes had the most perturbed transcriptome of the
assayed cell types, but neurons and microglia also
demonstrated a signiﬁcant increase in the expression of
tumor necrosis factor alpha (TNF-α) (Fig. 1). This ﬁnding
was validated with Western blot and immunoﬂuorescence
and suggests that this cytokine is a primary molecular signal
in the negative emotional sequelae of opioid withdrawal.
TNF-α has been shown to lower neuronal excitation
threshold resulting in an increased probability of actional
potential ﬁring (Schäfers and Sorkin, 2008; Vezzani and
Viviani, 2015). Taken together, these ﬁndings suggest TNF-α

FIGURE 1. Boxplots of select genes demonstrating signiﬁcant differential gene expression.
Statistics were calculated using nested ANOVA ( p < 0.05,  p < 0.01,  p < 0.0001 n = 4 animals for all treatments). Originally published in
O’Sullivan et al. (2019).
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paracrine signaling, likely mediated by astrocytes, in the CeA
during opioid withdrawal may lead to hyperactivity that
contributes to negative emotion and reinforcement of drug taking.
At the systems level, the CeA has strong bidirectional
connections to the nucleus tractus solitarius (NTS)—the
primary viscerosensory nucleus in the central nervous
system (Schwaber et al., 1982). This neuroanatomy suggests
that the emotions experienced secondary to limbic activity
are substantially inﬂuenced by peripheral feedback; an
insight that has been shown convincingly (Maniscalco and
Rinaman, 2018). Additionally, we found that gut microﬂora
demonstrated remarkable perturbation in opioid withdrawal
(Fig. 2) (O’Sullivan et al., 2019). This ﬁnding was correlated
with astrocyte activation in the amygdala suggesting these
two observations may be linked via interoceptive vagal
afferents and the NTS.
These single-cell ﬁndings translate to the behavioral level
as well. We conjecture that these connections form a visceralemotional neuraxis in which peripheral perturbation sensed
by vagal afferents is transmitted to the amygdala forming an

interoceptive antireward pathway (O’Sullivan and Schwaber,
2021). This antireward circuit is inhibited by drug use and
stimulated by substance withdrawal. We hypothesize that
the mesolimbic dopamine reward pathway functions in
parallel to this circuit with inverse activity consistent with
the opponent-process model (Pierce and Kumaresan, 2006;
Wise, 2008; Solomon and Corbit, 1974). These reward and
antireward pathways combine to provide positive and
negative motivators that reinforce behavior. Compulsive
drug-seeking and taking, then, is an imbalance in this
behavioral paradigm that is inﬂuenced at the molecular level.
This model informs future studies and the mechanism of
action of recent therapies. Astrocyte-mediated inﬂammation in
CeA has been demonstrated to provoke anxiety-like behavior,
(Yang et al., 2016) but the temporal dynamics of this process
in opioid withdrawal and the contribution of visceral
feedback remain unknown. Subdiaphragmatic vagotomy
studies in rat methamphetamine self-administration suggest
this circuit has an important inﬂuence on addiction
(Everett et al., 2021), but further investigation is warranted.

FIGURE 2. Relative abundance of gut
microﬂora from rat cohort.
Barplots display relative abundance of
bacterial species (-ΔΔCt values). #p <
0.1, *p < 0.05, **p < 0.008, ***p =
0.0009; two-way ANOVA n = 4
animals for each treatment. Originally
published in O’Sullivan et al. (2019).
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Moreover, anti-neuroinﬂammatory interventions such as
ibudilast have shown promise in treating addiction to
multiple substances in clinical trials (Cooper et al., 2016;
Heinzerling et al., 2020; Worley et al., 2016; Metz et al., 2017;
Comer and Johnson, 2013). It reduced the physical and
emotional symptoms of opioid withdrawal syndrome.
Furthermore, there is evidence that ibudilast’s mechanism of
action may be a peripheral decrease in inﬂammation
consistent with our model (Li et al., 2020). Indeed, peripheral
stimulation for opioid withdrawal syndrome has recently
been approved by the FDA (Miranda and Taca, 2018). The
BRIDGE device provides peripheral simulation to auricular
cranial nerves during opioid withdrawal and investigators
have shown that this input decreases neuronal ﬁring in the
amygdala via the NTS. This device likely treats opioid
withdrawal symptoms by decreasing CeA neuronal activity
via peripheral stimulation consistent with our ﬁndings and
model (O’Sullivan et al., 2019; O’Sullivan and Schwaber,
2021; O’Sullivan et al., 2021).
In conclusion, single-cell studies are situated at a unique
level of biological analysis that is particularly fruitful for
developing much needed psychiatric treatments. Single-cell
experiments with a network focus not only inform our
understanding of neural circuits, but also paracrine signaling
by a spectrum of cell types and provide context for organ
systems and behavioral understandings. The models
generated from such studies require validation by more
mechanistic approaches, but these models and the
hypotheses they suggest can provide insight into the
mechanisms of action of novel therapies.
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